Ivermectin Cancer Hype Sparks Fierce Backlash

A new patient cohort is touting big cancer gains from ivermectin, but top cancer groups say the evidence is not there yet.

Story Highlights

A 197-patient prospective cohort reported high self-reported benefit from ivermectin plus mebendazole.
The study lacked a control group and mixed many tumor types, limiting firm conclusions.
A small early study with ivermectin and immunotherapy saw one partial response among eight patients.
The American Cancer Society says ivermectin is not approved for cancer and lacks proven benefit.

What the new cohort claims and why it is drawing attention

Researchers tracked 197 cancer patients who received compounded ivermectin and mebendazole through a telemedicine service. Of 122 who reached six months, most reported some clinical benefit, including no evidence of disease, regression, or stable disease. The authors called it “real world” and said it was prospectively collected. Supporters argue the size and design justify more trials and public data releases to verify outcomes and safety signals.

The reported clinical-benefit figure grouped very different outcomes together. “Stable disease” sat beside “regression” and “no evidence of disease.” Without randomization or a control arm, those labels are not proof that ivermectin or mebendazole caused the changes. Many patients also received standard cancer care, which makes it hard to separate drug effects from chemotherapy, immunotherapy, or normal disease course.

What stronger evidence would look like

Oncology relies on randomized, controlled trials that compare new treatments to standard care or placebo. These trials use clear endpoints like overall survival and progression-free survival. They also include independent imaging review and safety tracking. Advocates want trials that stratify by tumor type, stage, and treatment history, and that publish full protocols, datasets, and adverse events. That path could confirm or refute the signals seen in the observational cohort.

A registered trial known as ICONIC plans to test ivermectin with immune checkpoint drugs in adults with solid tumors. The listing describes safety measures, immune readouts, and dose levels to study how the drug affects the body and tumors. Those details matter because lab studies do not prove benefit in people. Only well-run human trials can show if the drug helps patients live longer or feel better without unsafe harms.

What earlier human results show so far

An early study in metastatic triple-negative breast cancer tested ivermectin with immunotherapy in a tiny group. One patient had a partial response, one had stable disease, and six had progression. That small sample cannot guide care. It does show why large, controlled trials are needed to see if any group benefits and at what dose, schedule, or combination. Until then, claims of broad cancer control remain unproven in humans.

Laboratory and animal studies have suggested tumor growth slowdowns and effects on cell pathways. Those findings explain why researchers are curious, but they do not prove that typical human doses can reach the right levels in tumors. Reviews stress that dose, safety, and real patient outcomes must come from clinical research, not petri dishes or mice. Many repurposed drugs look promising early and then fail in trials.

What major cancer groups and clinicians advise now

The American Cancer Society says ivermectin is not approved to treat cancer. It warns that there is not enough human evidence to show it works against cancer. It also cautions that large doses can cause serious harm, and side effects can stack on top of chemotherapy or radiation effects. Its guidance is to use ivermectin for cancer only in a clinical trial where safety and results are tracked.

🚨 DR. WILLIAM MAKIS SPARKS DEBATE OVER REPURPOSED ANTIPARASITIC DRUGS IN CANCER RESEARCH

🔬 Fenbendazole is commonly used in veterinary medicine, while mebendazole is an established human antiparasitic drug. Researchers have also investigated mebendazole’s potential against… pic.twitter.com/7347PJbUoD

— GENIX MEDS | BUY IVERMECTIN,MEBENDAZOLE AND MORE (@genixmeds) October 16, 2026

Patient advocates on the left and right share a common worry: life-saving research moves too slowly, and low-cost drugs may get ignored. That frustration is real. But skipping trials can also hurt patients and hide the truth. The fastest honest answer comes from transparent, well-powered studies that any side can trust. Demand complete trial data, independent reviews, and clear safety reporting. That is how we cut through hype, protect patients, and hold institutions to account.